Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma—A Scoping Review
Microorganisms · 21.09.2023 · 11 (9) · 2363
DOI: 10.3390/microorganisms11092363 ↗Kurz gefasst
Scoping Review in der Zeitschrift Microorganisms, online erschienen am 21.09.2023. Verfasst von Ann-Kathrin Lederer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Transplant Surgery, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancers of the biliary tract are more common in Asia than in Europe, but are highly lethal due to delayed diagnosis and aggressive tumor biology. Since the biliary tract is in direct contact with the gut via the enterohepatic circulation, this suggests a potential role of gut microbiota, but to date, the role of gut microbiota in biliary tract cancers has not been elucidated. This scoping review compiles recent data on the associations between the gut microbiota and diagnosis, progression and prognosis of biliary tract cancer patients. Systematic review of the literature yielded 154 results, of which 12 studies and one systematic review were eligible for evaluation. The analyses of microbiota diversity indices were inconsistent across the included studies. In-depth analyses revealed differences between gut microbiota of biliary tract cancer patients and healthy controls, but without a clear tendency towards particular species in the studies. Additionally, most of the studies showed methodological flaws, for example non-controlling of factors that affect gut microbiota. At the current stage, there is a lack of evidence to support a general utility of gut microbiota diagnostics in biliary tract cancers. Therefore, no recommendation can be made at this time to include gut microbiota analyses in the management of biliary tract cancer patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General, Visceral and Transplant Surgery, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany.
- Center for Complementary Medicine, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
- Institute of Medical Biometry and Statistics (IMBI), Faculty of Medicine and Medical Center, University of Freiburg, 79104 Freiburg, Germany.
- Institute of Medical Microbiology and Hygiene, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
ORCID-Profile: Clemens Kreutz, Mohamed Tarek Badr, Fabian Bartsch
Zitieren
APA
Lederer, A. K., Rasel, H., Kohnert, E., Kreutz, C., Huber, R., Badr, M. T., Dellweg, P. K. E., Bartsch, F., & Lang, H. (2023). Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma—A Scoping Review. Microorganisms, 11(9), 2363. https://doi.org/10.3390/microorganisms11092363
Vancouver
Lederer AK, Rasel H, Kohnert E, Kreutz C, Huber R, Badr MT, et al. Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma—A Scoping Review. Microorganisms. 2023;11(9):2363. doi:10.3390/microorganisms11092363
BibTeX
@article{Lederer2023,
author = {Lederer, Ann-Kathrin and Rasel, Hannah and Kohnert, Eva and Kreutz, Clemens and Huber, Roman and Badr, Mohamed Tarek and Dellweg, Patricia K E and Bartsch, Fabian and Lang, Hauke},
title = {Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma—A Scoping Review},
journal = {Microorganisms},
year = {2023},
volume = {11},
number = {9},
pages = {2363},
doi = {10.3390/microorganisms11092363}
}
EUVIMED